Market Overview

Brean Capital Says Regeneron Pharma Robust Pipeline Drives Upside, Calls Out Dupilumab As Next Catalyst

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for REGN

DateFirmActionFromTo
May 2017Canaccord GenuityUpgradesHoldBuy
Mar 2017UBSInitiates Coverage OnBuy
Feb 2017PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (REGN)